Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial

Author： Cohen C.   Nieto-Cisneros L.   Zala C.   Fessel W. J.   Gonzalez-Garcia J.   Gladysz A.   McGovern R.   Adler E.   McLaren C.    

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.21, Iss.10, 2005-10, pp. : 1683-1692

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: An open-label randomized controlled trial

By Andersson Lars-Magnus  

Scandinavian Journal of Infectious Diseases, Vol. 45, Iss. 7, 2013-07 ,pp. : 543-551

Informa Healthcare

Access to resources Recommend Favorite

Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naïïve human immunodeficiency virus-1 patients in Sweden

By Thuresson Per-Olof   Heeg Bart   Lescrauwaet Benedicte   Sennfäält Karin   Alaeus Annette   Neubauer Aljoscha  

Scandinavian Journal of Infectious Diseases, Vol. 43, Iss. 4, 2011-04 ,pp. : 304-312

Informa Healthcare

Access to resources Recommend Favorite

Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir

By Calza Leonardo   Trapani Filippo   Salvadori Caterina   Magistrelli Eleonora   Manfredi Roberto   Colangeli Vincenzo   Di Bari Maria Assunta   Borderi Marco   Viale Pierluigi  

Scandinavian Journal of Infectious Diseases, Vol. 45, Iss. 2, 2013-02 ,pp. : 147-154

Informa Healthcare

Access to resources Recommend Favorite

Safety, Efficacy and Development of Resistance under the New Protease Inhibitor Lopinavir/Ritonavir: 48-Week Results

By Voigt E.   Wasmuth J.-C.   Vogel M.   Mauss S.   Schmutz G.   Kaiser R.   Rockstroh J.-K.  

Infection, Vol. 32, Iss. 2, 2004-04 ,pp. : 82-88

Springer Publishing Company

Access to resources Recommend Favorite

Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: Prevalence and predictors

By Giambenedetto Simona Di   Bacarelli Alessanra   Pinnetti Carmen   Colafigli Manuela   Prosperi Mattia   Gatti Giorgio   Cauda Roberto   De Luca Andrea  

Scandinavian Journal of Infectious Diseases, Vol. 39, Iss. 9, 2007-01 ,pp. : 813-818

Informa Healthcare

Access to resources Recommend Favorite